✦ LIBER ✦

Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents

✍ Scribed by Kittner, Jens M.; Weiss, Nora M.; Wiltink, Jörg; Schattenberg, Jörg M.; Grambihler, Annette; Thieringer, Florian; Weinmann, Arndt; Zimmermann, Tim; Koch, Sandra; Schuchmann, Marcus; Galle, Peter R.

Book ID: 122267384
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 186 KB
Volume: 46
Category: Article
ISSN: 1590-8658
DOI: 10.1016/j.dld.2013.08.139

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

839 DEFER OR TREAT NOW? REASONS FOR THER

839 DEFER OR TREAT NOW? REASONS FOR THERAPEUTIC DECISIONS IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 IN THE EARLY ERA OF DIRECTLY ACTING ANTIVIRALS

✍ Kittner, J.M.; Weiss, N.; Schattenberg, J.M.; Grambihler, A.; Sprinzl, M.F.; Thi 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Clinical utility of the ARCHITECT HCV Ag

Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection

✍ Johannes Vermehren; Simone Susser; Annemarie Berger; Dany Perner; Kai-Henrik Pei 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 300 KB

1165 CLINICAL UTILITY OF THE ARCHITECT H

1165 CLINICAL UTILITY OF THE ARCHITECT HCV AG ASSAY FOR EARLY TREATMENT RESPONSE MONITORING IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 INFECTION

✍ Vermehren, J.; Süsser, S.; Berger, A.; Perner, D.; Peiffer, K.H.; Zeuzem, S.; Sa 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Randomized, double-blind, placebo-contro

Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection

✍ Peter Ferenci; Elisabeth Formann; Hermann Laferl; Michael Gschwantler; Franz Hac 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 182 KB